Please sign in to follow a disease.
Blood test may spot lung cancer early
NCT ID NCT07182214
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is looking at whether a blood test (called a liquid biopsy) can help detect lung cancer. Researchers will collect blood samples from 1,340 people, some with lung nodules and some without, to measure specific molecules called miRNA and DNA methylation. The goal is to see if these markers can tell the difference between people who have lung cancer and those who don't.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to help detect lung cancer earlier, potentially improving outcomes.
- What could go wrong
- This is an early observational study, not a treatment trial. It may not prove the test is accurate enough for widespread use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,340 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants in the test group must have identified lung nodules or masses through low-dose computed tomography (LDCT)CT scan, and have a scheduled medical operation, which is not limited to surgical excision. Control group participants should have no significant findings in LDCT/CT scan displaying either no nodules, or nodules smaller than 6mm were assessed by investigators without clinically significant justification, through an axial resolution of 3 mm or less, within 2 months prior to their enrollment in the study.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Female or male participants at least 18 years of age 2. Participants in the test group must have identified lung nodules or masses through low-dose computed tomography (LDCT)CT scan, and have a scheduled medical operation, which is not limited to surgical excision. Control group participants should have no significant findings in LDCT/CT scan displaying either no nodules, or nodules smaller than 6mm were assessed by investigators without clinically significant justification, through an axial resolution of 3 mm or less, within 2 months prior to their enrollment in the study. 3. Participants in the test group should be treatment naïve. 4. Ability to complete a questionnaire, comprehend and comply with the requirements of the study 5. Written informed consent, and authorization to use and disclose health information Exclusion Criteria: 1. Has any history of cancer diagnosis 2. Has received a blood transfusion (except for autologous blood transfusion) within the first two months prior to participating the trial 3. Is participating in a clinical trial (the non-intervention trial will be accepted) 4. Has taken gene therapy within one year prior to participating the trial 5. Has any vaccinations within 3 months prior to blood sample collection 6. Is currently pregnant 7. Has any severe acute or uncontrolled chronic lung disease such as pneumonia, lung abscess, acute exacerbation of COPD or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of Study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this Study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Pharus Taiwan, Inc.
RECRUITINGHsinchu, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Can AI make lung cancer scans easier to read?
- Two-Drug combo targets Treatment-Resistant lung cancer
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- App aims to catch a hidden radiotherapy side effect
- Which nerve block wins for lung surgery pain?